ResearchMoz presents this most up-to-date research on Research on China Diagnostic Reagent Industry, 2015.
After 30 years of development, the China's diagnostic reagent industry achieved a market size of nearly RMB 20 billion in 2014, a YoY growth of 15.7%. Currently nearly 90% downstream users of China's diagnostic reagent market comes from hospitals.
There's still a huge growth potential in China's diagnostic reagent industry. China accounts for 20% of total population worldwide, but only take up 7% of global diagnostic reagent market in 2014. The average diagnostic reagent expense in China is only around $3, far below the average of $28 in the developed countries.
Currently there are about 300 diagnostic reagent enterprises in China and the industry concentration is still low. Large companies in China include: KHB, Da An Gene, Maker, HTA etc. Foreign brands accounts for over 50% of China's diagnostic reagent market in 2014, especially in high-end fields. The market share of domestic enterprises mainly comes from biochemical reagents.
China has fulfilled the import substitution of biochemical reagents, intensified competition has largely squeezed the profits in this subfield. Chemiluminescence Immunoassay (CLIA) and molecular diagnosis will be the most promising subfields in China's diagnostic reagent industry.
New Industries Biomedical Engineering Co., Ltd is the leading CLIA enterprise in China. Currently the company owns 102 chemiluminescent reagents and 8 models of CLIA analyzer. The company achieved reagents sales of RMB 331 million and reagents products has exported to Swiss, France, and Italy etc.
Zeesan Biotech is the leading molecular diagnosis enterprise in China. The company achieved molecular diagnosis reagents sales of RMB 11.85 million in 2014. Zeesan's products covers infectious disease (mainly phthisis), tumor (mainly leukemia) and genetic disease.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=285875
Table of Content
3 Major Enterprises
3.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
3.1.1 Company Profile
3.1.2 Key Financial Data
3.1.3 Competitiveness Analysis
3.1.7 Diagnostic Reagent Business
3.2 Beijing Strong Biotechnologies, Inc (BSBE)
3.2.1 Profile
3.2.2 Key Financial Data
3.2.3 Competitiveness Analysis
3.2.4 Diagnostic Reagent Business
3.3 Da An Gene
3.3.1 Company Profile
3.3.2 Key Financial Data
3.3.3 Competitiveness Analysis
3.3.4 Diagnostic Reagent Business
3.4 Fosun Pharmaceutical
3.4.1 Company Profile
3.4.2 Key Financial Data
3.4.3 Competitiveness Analysis
3.4.4 Diagnostic Reagent Business
3.5 Beijing Leadman Biochemistry Co., Ltd.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=285875
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
After 30 years of development, the China's diagnostic reagent industry achieved a market size of nearly RMB 20 billion in 2014, a YoY growth of 15.7%. Currently nearly 90% downstream users of China's diagnostic reagent market comes from hospitals.
There's still a huge growth potential in China's diagnostic reagent industry. China accounts for 20% of total population worldwide, but only take up 7% of global diagnostic reagent market in 2014. The average diagnostic reagent expense in China is only around $3, far below the average of $28 in the developed countries.
Currently there are about 300 diagnostic reagent enterprises in China and the industry concentration is still low. Large companies in China include: KHB, Da An Gene, Maker, HTA etc. Foreign brands accounts for over 50% of China's diagnostic reagent market in 2014, especially in high-end fields. The market share of domestic enterprises mainly comes from biochemical reagents.
China has fulfilled the import substitution of biochemical reagents, intensified competition has largely squeezed the profits in this subfield. Chemiluminescence Immunoassay (CLIA) and molecular diagnosis will be the most promising subfields in China's diagnostic reagent industry.
New Industries Biomedical Engineering Co., Ltd is the leading CLIA enterprise in China. Currently the company owns 102 chemiluminescent reagents and 8 models of CLIA analyzer. The company achieved reagents sales of RMB 331 million and reagents products has exported to Swiss, France, and Italy etc.
Zeesan Biotech is the leading molecular diagnosis enterprise in China. The company achieved molecular diagnosis reagents sales of RMB 11.85 million in 2014. Zeesan's products covers infectious disease (mainly phthisis), tumor (mainly leukemia) and genetic disease.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=285875
Table of Content
3 Major Enterprises
3.1 Shanghai Kehua Bio-engineering Co., Ltd. (KHB)
3.1.1 Company Profile
3.1.2 Key Financial Data
3.1.3 Competitiveness Analysis
3.1.7 Diagnostic Reagent Business
3.2 Beijing Strong Biotechnologies, Inc (BSBE)
3.2.1 Profile
3.2.2 Key Financial Data
3.2.3 Competitiveness Analysis
3.2.4 Diagnostic Reagent Business
3.3 Da An Gene
3.3.1 Company Profile
3.3.2 Key Financial Data
3.3.3 Competitiveness Analysis
3.3.4 Diagnostic Reagent Business
3.4 Fosun Pharmaceutical
3.4.1 Company Profile
3.4.2 Key Financial Data
3.4.3 Competitiveness Analysis
3.4.4 Diagnostic Reagent Business
3.5 Beijing Leadman Biochemistry Co., Ltd.
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=285875
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
No comments:
Post a Comment